Malic Enzyme - The Journal of Biological Chemistry

9 downloads 106 Views 1MB Size Report
Oct 8, 1991 - Jan K. Teller$, Leonard A. Fahient, and John W. Davis. From the Department of Pharmology, University of Wisconsin Medical School, Madison, ...
Vol. 267, No. 15, Issue of May 25, pp. 10423-10432,1992 Printed in U.S.A.

THEJOURNAL OF BIOLOGICAL CHEMISTRY Q 1992 hy T h e American Society for Biochemistry and Molecular Biology, Inc.

Kinetics and Regulation of Hepatoma MitochondrialNAD(P) Malic Enzyme* (Received for publication, October 8, 1991)

Jan K.Teller$, LeonardA. Fahient, and JohnW.Davis From the Department of Pharmology, University of Wisconsin Medical School,Madison, Wisconsin 53706

Kinetic studies of Morris7777 hepatoma mitochon- of liver, regenerating liver, and many other organs, but is drial NAD(P) malic enzyme were consistent with an present in tumor mitochondria in levels proportional to the ordered mechanism where NAD adds to the enzyme rapidity of cell division (7). However, in tumor mitochondria, before malate and dissociationof NADH from the en- the level of NAD(P) malic enzyme activity is stillconsiderably zyme is rate-limiting. In addition to its active site, lower than that of malate dehydrogenase ((S)-malate:NAD+ malate apparently also associates with a loweraffinity oxidoreductase, EC 1.1.1.37) (1, 7-9). In spite of this, when with an activator site. The activator fumarate com- malate is supplied to tumor mitochondria, it can be channeled petes with malate at the activator site and facilitates exclusively into NAD(P) malic enzyme so that pyruvate and dissociation ofNADH fromthe enzyme. The ratio of NAD(P) malic enzymeto malate dehy- COz are the major products and both are produced at equivdrogenase activity in the hepatoma mitochondrialex- alent rates (1,7). It is not known if NAD(P) malic enzyme is the same in all tract was found to be too low, even in the presence of known inhibitorsof malate dehydrogenase, to account rapidly dividing tumors. Therefore, we have made a detailed for the known ability of NAD(P) malic enzyme to in- kinetic study of this enzyme, which we recently purified from tercept exogenous malate from malate dehydrogenasethe Morris 7777 hepatoma (13), and compared the results in intact tumor mitochondria (Moreadith, R. W.,and with those found previously in less detailed kinetic studies of Lehninger, A. L. (1984) J. Biol. Chem. 259, 6215- NAD(P) malic enzyme purified from the 22 aH hepatoma (8). 6221).However, NAD(P) malic enzyme may be ableto Also, some important kinetic properties of NAD(P) malic intercept exogenous malate because according to the enzyme are compared with those of malate dehydrogenase to present results, it can associatewith the pyruvate de- further characterize competition between these two enzymes hydrogenase complex, which could localize NAD(P) for malate. malic enzyme in the vicinity of the inner mitochondrial It can be calculated from previous results that in Ehrlich membrane. mitochondria, the specific activity of alanineaminotransThe activity levels of some key metabolic enzymes ferase with pyruvate as a substrate would be at least 5-fold were found to be different in Morris 7777 mitochon- higher than thatof the fully activatedpyruvate dehydrogenase dria than in liver or mitochondria of other rapidly complex (1,14-18). However, when Ehrlich tumor mitochondividing tumors. These results are discussed in terms of differences among tumors in their ability to utilize dria are supplied with glutamate plus malate, even in the absence of ADP, about half of the pyruvate generated by malate, glutamate, andcitrate as respiratory fuels. NAD(P) malic enzyme reacts with each of these two enzymes (1).This suggests that the pyruvate dehydrogenase complex may associate with NAD(P) malic enzyme with the result Insight into glutamate-malate metabolism is quite impor- being that pyruvate generated by NAD(P) malic enzyme is a tant in rapidly dividing tumors because glutamate derived better substrate than free pyruvate for the pyruvate dehydrofrom glutaminase instead of glucose is their major source of genase complex. Therefore, in this paper,we have also invesenergy (1-5). One reason glucose is not a major source of tigatedinteractions between the pyruvate dehydrogenase energy is that pyruvate is readily converted into lactate by complex and NAD(P) malic enzyme. the high levels of lactate dehydrogenase in thetumor cytosol MATERIALSANDMETHODS (4, 6 ) . Consequently, tumor mitochondria adapt to this and Enzymes and Reagents-Bovine heart pyruvate dehydrogenase and other metabolic abnormalities by having high levels of glutaa-ketoglutarate dehydrogenase complexes, bovine and rat liver miminase to facilitate utilization of glutamate as afuel and high tochondrial glutamate dehydrogenases, aspartate aminotransferase, levels of NAD(P) malic enzyme (EC 1.1.1.39) so that pyruvate and Morris 7777 hepatoma mitochondrial NAD(P) malicenzyme can be produced from malate within the mitochondria (1-5, were prepared as described previously (13, 19-23). Pig heart mito7-12). chondrial malate dehydrogenase, citrate synthase,and fumarase were NAD(P) malic enzyme is essentially absent inmitochondria obtained from Boehringer Mannheim. Other enzymes, coenzymes,

* This work was supported by National Institutes of Health Grant CA 40445. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “aduertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. $ Present address: Dept. of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, Great Britain. § To whom reprint requests should be addressed Dept. of Pharmacology, University of Wisconsin Medical School, 1300 University Ave., Madison, WI 53706.

substrates, and reagents were obtained from Sigma. Stock solutions of all reagents used in assays were adjusted to the pH of the assay. Solutions of succinyl-CoAwere prepared fresh daily, and theconcentrations of succinyl-CoA and acetyl-coA were measured as described previously (19). Methods used to dialyze or chromatograph enzymes on Sephadex G-200 or G-25 and to prepare enzyme for use in these experiments were described previously (19,24). Concentrations of Enzyme and Protein-The concentrations of pure pyruvate dehydrogenase complex, a-ketoglutarate dehydrogenase complex, and NAD(P) malic enzyme were measured as described previously with bovine serum albumin as a standard (25, 26). The

10423

10424

Regulation of Hepatoma Glutamate-Malate Metabolism

concentrations of pure glutamate dehydrogenase, malate dehydrogenase, and citrate synthase were measured spectrophotometrically at 280 nmas described previously (19,24). The concentration of protein in mitochondrial extracts was measured by the biuret reaction on trichloroacetate precipitates of the extracts (26). Obtaining and Analyzing Kinetic Data-Michaelis constants were obtained from the Michaelis-Menten relationship as described previously (19). The effects of allosteric modifiers of NAD(P) malic enzyme in the presence of constant levels of substrates were evaluated with Equation 1 for an activator (A) or Equation 2 in the case of an inhibitor (I) as described previously (27,28).

In Equations 1 and 2, Au is the change in velocity produced by the modifier, V is the velocity in the absence of modifier, VAand Vi are the velocities in the presence of saturating modifier, and KOand K, are the apparent dissociation constants of the modifier. Equations 1 and 2 are empirically identical to the Michaelis-Menten equation. Therefore, data corresponding to Equations 1 and 2 were directly fitted to these equations using the nonlinear regression computer program. Product inhibition data were analyzed using the least squares method as described previously (29). Non-Michaelis-Menten kinetic results were evaluated as described previously (30) and in the text. Each experiment was the average of three experiments. Standard errors were 4 0 % of the mean. The quite lowK,of oxalacetate in the malate dehydrogenase reaction was measured spectrophotometrically at 340 nm with a Cary high-performance spectrophotometer from Varian Associates, Inc. Preparation and Assay of Enzymes in Mitochondrial ExtractsMitochondria were isolated from the viable tissue of Morris 7777 hepatomas (initially provided by Dr. Michael Lee, New Jersey Medical School), mitochondrial extracts were prepared, and enzymes were assayed with the same methods (Methods I and I1 (31) plus additional methods) used in the accompanying article to measure enzyme levels in liver mitochondria (31). With the exceptions of the enzymes noted below, all extraction procedures yielded comparable levels of enzyme activity. Whereas incubation with uncoupling agents (31, 32) appeared to activate the pyruvate dehydrogenase complex maximally in liver mitochondria, its activity in the hepatoma mitochondria was further increased (1.5-fold) on incubation of the mitochondria (9 mgof protein/ml) in 0.5% Triton X-100, 50 mM NaHepes' (pH 7.5), 1 mM dithiothreitol, 20 @g/mlleupeptin, 1 mM azide, 5 mM MgCL, and 1 mM dichloroacetate for 20 min at 30 "C. Because relatively large amounts of protein (-0.5 mg)were required for assay of alanine aminotransferase activity in the tumor extracts, it was centrifuged briefly at 3000 x g to reduce its turbidity. Alanine aminotransferase activity was not detected in the 3000 X g precipitate. In addition to Method I. assays for NAD:isocitrate dehydrogenase were also performed with mitocGondria that were homogenizedin 0.1 M potassium phosphate (pH 7.6), 1 mM ADP, 1 mM dithiothreitol, 0.1 mM EDTA, 10 pg/ml leupeptin, and 0.5% Triton X-100. The activity of NAD:isocitrate dehydrogenase was the same in liver mitochondria as reported previously (31), but the activity in hepatoma mitochondria was -1.2-fold lower. Assays for NAD(P) malic enzyme were also performed with mitochondria that were homogenized in 50 mM Bes/triethanolamine (pH 7.2), 1 mM dithiothreitol, 1 mM EDTA, 0.5% Triton X-100, 10 pg/ml leupeptin, and 5 mM fumarate. Similar results were obtained with mitochondria prepared with this and the previously described method (Method I) (31). For assays of NAD(P) malic enzyme, the medium contained the same buffer used for preparing the mitochondrial extract together with 5 PM rotenone, 1.0 mM NADP, 10 mM malate, and 5 mM MgCl,. The reaction was started with Mn2+ after constant a rate ( 4 0 % that with MnZ+)was established in its absence. Added fumarate had no effect. As a test for the strictly NADP-dependent malic enzyme, the extract was assayed at low concentrations of malate (2 mM) and

NADP (0.2mM) in the presence of 1 mM ATP and 2 mM MgCl,, conditions under which NAD(P) malic enzyme is largely inactive. In agreement with previous studies (7) of Morris 7777 hepatoma mitochondria, there was no NADP malic enzyme activity. Hepatoma mitochondrial extracts were also prepared with a microtip sonicator (Method 111) as described previously (13). The conditions for enzyme assays with these extracts at 25 "C were as follows: NAD(P) malic enzyme: 10 mM malate, 1 mM NADP, 10 mM MnCl,, 5 mM fumarate, 50 mM Tris-HC1 (pH 7.4), 0.1 mM EDTA, and 0.5 mM dithiothreitol; and malate dehydrogenase: 20 mM potassium phosphate (pH 7.0), 0.1 mM EDTA plus 0.1 mM oxalacetate and 0.1 mM NADH. Under these assay conditions, the specific activity of pure Morris 7777 hepatoma mitochondrial NAD(P) malic enzyme is 11 rmol/min/mg (13). Other enzyme assays were performed as described previously (31), and specific activities are expressed as micromoles of product/minute/milligram of protein. The forward malate dehydrogenase reaction was assayed in mitochondrial extracts in the presence of 1.0 mM NAD, 1.0 mM malate, 0.1 mM acetyl-coA, and 20 rg/mlcitrate synthase as described previously (24). With the exception of the alanine aminotransferase reaction (which, as mentioned above, was assayed in a centrifuged extract), all enzyme assays and measurements of protein concentrations were performed with uncentrifuged extracts. RESULTS

Regulation of NAD(P) Malic Enzyme by Substrates and Fumarate-A series of kinetic experiments were performed under conditions (50 mM Tris-HC1, 10 mM MnC12, 0.1 mM EDTA, and 0.5 mM dithiothreitol (pH 7.4)) comparable to those employed previously instudies of mitochondrial NAD(P) malic enzyme purified from 22 aH hepatoma mitochondria (8).Under these conditions and when NAD was the coenzyme, double-reciprocal plots of the velocity of Morris 7777 mitochondrial NAD(P) malicenzyme uersus malate concentration were not linear unless the allosteric activator fumarate was also present (Fig. 1).These results were consistent with Equation 3, the rate equation for Mechanism I, where malate (B) is bound to the active site of the oxidized coenzyme-enzymecomplex (E.A);and in the absence of fumarate,malate is also bound with a considerably lower affinity to anallosteric activator site. Fumarate (F), however, competes with and thereby prevents binding of malate at the activator site so that, in the presence of fumarate, doublereciprocal plots of velocity uersus malate concentration are linear.

I

t

I

0.5t

I

-2.5

I

A

Y I

/

2.5

5.0

I/[Molate]mM-l

FIG. 1. Double-reciprocal plotsof specific activityof Morris 7777 NAD(P) malic enzyme uersus malate concentration.

Assays were performed in the presence of 1.0 mM NAD and either the presence (curue B ) or absence (curue A ) of 5.0 mM fumarate. The solid curue A was calculated using Equation 3 and the values for the ' The abbreviations used are: Hepes, N-2-hydroxyethylpiperazine- constants shown in TableI. Remaining experimental conditions were N'-2-ethanesulfonic acid; Bes, N,N-bis(2-hydroxyethyl)-2-amino- 50 mM Tris-HCI, 10 mM MnC12, 0.1 mM EDTA, and 0.5 mM dithiothreitol (pH 7.4) at 25 "C. ethanesulfonic acid.

Regulation of Hepatoma Glutamate-Malate Metabolism

10425 I

I

0 30

BEA

MECHANISM I

TABLEI Kinetic constants of tumor mitochondrial NAD(P) malic enzyme in 50 mM Tris-HCI, 10 mM MnC& (pH 7.4) at 25 "C Kinetic constants were obtained from the results shown in Figs. 1-3 and Equations3 and 4. Assays also contained 0.1 mM EDTA and 0.5 mM dithiothreitol. The termKa refers to theK,,, of NAD.

s22:!e

Fixed substrate [Fumarate] mM

Malate Malate Malate Malate NAD NAD

NAD (1.0 mM) NAD (1.0 mM) NADP (1.0 mM) NADP (1.0 mM) Malate (10mM) Malate (10 mM)

0 5.0 0 5.0 0

5.0

Specific activity

Kinetic constant

VI Vz V, KI K z K7 pmollminl mM mg

5 10

FIG. 2. Double-reciprocal plots of specific activity of mitochondrial NAD(P) malic enzyme uersus NAD concentration. Assays were performed in the presence of 10 mM malate and either the presence (curve B ) or absence (curue A ) of 5.0 mM fumarate. Remaining experimental conditions are described in the legend to Fig. 1. "

KA I

4.O

0.8 8 18

17

1.2 12

15 11

16

1.4 0.028 0.024

In Equation 3, u is the initial velocity; [Eo] is the milligrams of enzyme/milliliter, and dissociation constants and rate constants for product-yielding steps are representedby K and k, respectively, as shown in Mechanism I. The solid curve (Fig. 1, curue A ) , obtained in the presence of NAD and absence of fumarate, was calculated from Equation 3 with [F] = 0, K1/K2being negligible, and the other constants equal to thevalues shown in Table I, where Vl, Vz, and V3 equal the maximal specific activities of the steps indicated by k l , kp,and k3, respectively, of Mechanism I. When fumarate is saturating (curue B ) , Equation 3 can be simplified to Equation 4, an equation of the Michaelis-Menten form.

J

/

3.0

/

I /v

/

I

/

/ 2.0 I

/

/

I .o

i

2.5

I/[Malate] mM" The values of the constants of Equation 4 are also shown in Table I. Thus, according to these results (Fig. l),binding of either malate orfumarate tothe activatorsite increases velocity at the active site, but the effect of fumarate is 1.8fold greater ( V2= 10, V3= 18) (Table I). Fumarateproduced a comparable increase (1.5-fold) in the K, of malate at the active site (K1= 0.8 mM, K7 = 1.2 mM) (Table I). In the presence of high levels of malate, double-reciprocal plots of velocity uersus NAD concentration were linear in either thepresence or absence of fumarate (Fig. 2). Fumarate again increased the maximal velocity -1.5-fold ( Vz = 11, V3 = 16) (Fig. 2 and Table I), butfumarate had no marked effect on theK,,, of NAD (Ka = 0.028 to 0.024 mM) (Fig. 2 and Table

I). When NADP was the coenzyme, double-reciprocal plots of velocity versus malate concentration were linear in both the presence and absence of fumarate (Fig. 3). Fumarate markedly decreased the K,,, of malate, but had little effect on the V,,, (Fig. 3 and TableI). These resultsindicate that in the absence of fumarate, NADP does not readily support binding of malate to theenzyme. Consequently, the K , of malate at the active

FIG. 3. Double-reciprocal plots of specific activity of mitochondrial NAD(P) malic enzyme uersus malate concentration. Assays were performed in thepresence of NADP (1.0 mM) and either the presence (curue B ) or absence (curue A ) of 5.0 mM fumarate. Remaining experimental conditions are described in the legend to Fig. 1.

site is high (Ki = 12 mM) (Table I), andbinding of malate to the activator site was not detected. Fumarate, however, now mainly activated by enhancing binding of malate to theactive site (K7= 1.2 mM). Fumarate had no significant effect on the maximal velocity ( V3= 15, Vl = 17) (Table I). Although NADP was not very reactive in the absence of fumarate, in the presence of fumarate, NADP was essentially as active as NAD. In both cases, the V,,, was 15-18 and the K,,, of malate was 1.2-1.4 mM (Table I). However, in the presence of both coenzymes and fumarate, the velocity and effect of lactate dehydrogenase on the reaction were about the same as in the presence of NAD alone (Table II), indicating thatas with otherNAD(P) malic enzymes, NAD is the preferred coenzyme (8, 33).

Regulation of Hepatoma Glutamate-Malate Metabolism

10426

TABLEI1 Activity of tumor mitochondrial NAD(P) m a l i c enzyme with NAD versus NADP Assays were performed in the presence of 10 mM malate, 5 mM fumarate, a 1.0 mM concentration of each coenzyme, and, where indicated, 5 pg/ml lactate dehydrogenase (LDH). Other conditions were the same as described in the legend to Table I. Specific activity Coenzyme

-LDH

NAD 12 NADP

NAD

+LDH

pmol reduced coenzyme accumulntedjminjmg 17 0

12 18

+ NADP

4

TABLE I11 Kinetic constants of tumor mitochondrial NAD(P) malic enzyme in 20 mMpotmsium phosphate, 2 mM MgCI, (pH 7.0) at 25 "c Kinetic constants were obtained by using Equations 3 and 4 as described in the text and the legend to Fig. 1. Assays also contained 0.1 mM EDTA and 0.5 mM dithiothreitol. The term KA refers to the K , of the coenzyme. suVbag:e

Fixed substrate

[Fumarate]

Specific activity

mM

VI Vz pmoljminj

Kinetic constant

KI

NAD (1.0 mM)

0

NAD (1.0 mM)

1.0

NADP (1.0 mM) 36 0 NADP 2.6 (1.0 mM) 0.58

1.0

Malate (1.0 mM) Malate (1.0 mM) Malate (1.0 mM) Malate (1.0 mM)

0 1.0 0 1.0

10.6 0.16 0.65

K3

Kn

mM

mg

Malate Malate Malate Malate NAD NAD NADP NADP

I/[NAD] mM"

FIG. 4. Doulile-reciprocal plots of specific activity of tumor NAD(P) malic enzyme uersus NAD concentration. Assays were performed in the presence of 10 mM malate and 5.0 mM fumarate. The concentrations of NADH were 0.2, 0.10, 0.05, 0.025, and 0 mM in curues A-E, respectively. Remaining experimental conditions are described in the legend to Fig. 1.

2

100

11 200 1.0

1.6

0.16 0.47 0.073 0.15

0.048 0.042 0.73 0.020

I

- 0 10

Reaction in Potassium Phosphate-The same type of kinetic pattern as described above was also found when tumor malic enzyme was assayed in potassium phosphate plus 2 mM MgClz at pH 7.0 (Table I11 and data not shown). Again, fumarate increased the linearity of double-reciprocal plots of velocity uersus malate concentration when NAD was the coenzyme, but now fumarate also slightly decreased the K,,, of malate at the active site (decreased K J (Table 111). Plots of the reciprocal of velocity uersus NAD concentration were also linear in phosphate buffer; and again, fumarate did not markedly alter the K,,, of NAD, but mainly activated by increasing the maximal velocity (Table 111). The reaction with NADP was also consistent with Michaelis-Menten kinetics in phosphate buffer; and again, the main effect of fumarate was to markedly decrease the K , of malate. The major difference between the NAD(P) malic enzyme under the two different assay conditions was found when NAD was the coenzyme and fumarate was absent. Under these conditions, the maximal velocity, when malate was bound only to its active site (VI = 0.16 uersus 5), and the affinity of malate for its allosteric site (K3 = 100 uersus 8) were both considerably lower in phosphate plus M e (Table 111) than in Trisplus Mn2+ (TableI). Regulation by Product-As shown in Figs. 4-7, in thepresence of fumarate, Mn2+, and Tris buffer, NADH was competitive with NAD and noncompetitive with malate. Plots of the reciprocal of velocity uersus NADHconcentration intersected at low levels of NADH, and theintersection points are shown in Table IV. The intersection points were even lower in the

I

0

I

0 10

J

0.20

[NADH] mM

FIG. 5. Plots of reciprocal of velocity of tumor NAD(P) malic enzyme uersus NADH concentration. The concentrations of NAD were 0.015, 0.05, 0.10, and 0.30 mM in curues A-D, respectively. Curue E shows the common intercept on the l / u axis of Fig. 4. Remaining experimental conditions are described in the legends to Figs. 1 and 4.

absence of fumarate (Figs. 8 and 9 and Table IV). Also, in the absence of fumarate, plots of velocity uersus NADH concentration deviated from linearity (NADH became more inhibitory) as the level of NAD was decreased (Fig. 8). In phosphate buffer plus Mf, NADH was also quite inhibitory, and NADPH was equally inhibitory. Again, inhibition was reduced by fumarate (Table V). Even 1.0 mM levels of pyruvate were not very inhibitory (Table V). Regulation by Activators or Inhibitors-Succinate was also an activator, but was less effective than fumarate (Kahigher and maximal activation lower) (Fig. 10 and Table VI). Oxalacetate was an inhibitor (Ki = 0.18mM), andsaturating oxalacetate inhibited 100% (Fig. 11). The rate equation for a mechanism where two modifiers compete for the same site can be obtained from Mechanism I and Equation 3 by substituting the second modifier (in this case, succinate or oxalacetate) for malate at the allosteric site (steps indicated by K2 and K3).According to therate equation for this mechanism, fumarate should increase the apparent dissociation constant of the second modifier, but should have

Regulation of Hepatoma Glutamate-Malate Metabolism

10427 I

I

L

-0 25

0 25

0

I

I

J

FIG. 8. Plots of reciprocal of velocity of NAD(P) malic enzyme versus NADH concentration in absence of fumarate. Assays were performed in the presence of 10 mM malate and 0.025, 0.05,0.1, and 0.3 mM NAD (curues A-D, respectively). Remaining experimental conditions aredescribed in the legend to Fig. 1.

05

I/ [Malate] rnM"

FIG. 6. Double-reciprocal plots of velocity of tumor NAD(P) malic enzyme versus malate concentration. Assays were performed in the presence of 1.0 mM NAD and 5.0 mM fumarate. The concentrations of NADH were 0.40, 0.20, 0.10, and 0 mM in curues A-D, respectively. Remaining experimental conditions aredescribed in the legend to Fig. 1.

[NADH] mM

FIG. 9. Plots of reciprocal of velocity of NAD(P) malic enzyme versus NADH concentration in absence of fumarate. Assays were performed in the presence of 1.0 mM NAD and 1.0, 2.5, 5, and 10 mM malate (curues A-D, respectively). Remaining experimental conditions aredescribed in the legend to Fig. 1. - 0 25

0

0 0

0 25

[NADH] rnM

FIG. 7. Plots of reciprocal of velocity of tumor NAD(P) malic enzyme versus NADH concentration. The concentrations

of malate were 2.5,5.0, and 10 mM in curues A-C, respectively. Remaining experimental conditions are described in the legends to Figs. 1 and 6.

TABLE V Inhibitors of tumor mitochondrial NAD(P) malic enzyme Assays were performed in the presence of 1.0 mM NAD, 10 mM malate,and, whereindicated, 1.0 mM fumarate. Remainingassay conditions were 20 mM potassium phosphate, 2 mM MgC12, 0.1 mM EDTA, and 0.5 mM dithiothreitol (pH 7.0) at 25 "C. Inhibition Inhibitor

TABLEIV Intersection points of plots of reciprocal of velocity uersus NADH concentration The intersection points were obtained from the results shown in Figs. 5 and 7-9. Remaining experimental conditions aredescribed in the legends to these figures and Fig. 1.

sz2:ie NAD NAD Malate Malate

substrate [Fumarate] Fixed

Malate (10 mM) Malate (10 mM) NAD (1.0 mM) NAD (1.0 mM)

Intersection point mM

mM

0 5.0 0 5.0

0.046 0.035 0.18

0.017

no effect on velocity when the second modifier is saturating and displaces fumarate from the enzyme. In agreement with this mechanism (Fig. 10, curve A ) , succinate inhibits in the presence of fumarate (because saturating succinate produces less of an increase in velocity than fumarate), andhigh levels of succinate are requiredfor inhibition (because fumarate and

+Fumarate -Fumarate %

NADH (0.1 mM) NADPH (0.1 mM) 24 (0.2 mM) Succinyl-CoA Acetyl-coA (0.2 mM) ATP (0.2 mM) 4 mM) ADP (0.2 ATP (1.0 mM) ADP (1.0 mM) Pyruvate (1.0 mM) Citrate (1.0 mM) Alanine (1.0 mM) Aspartate (1.0mM) Glutamate (1.0 mM)

43 46 24 2 10 6 49 26 18

19 2 0 0

31 31 18 8

39 19 7 18 5

0 0

succinate are competitive). However, in disagreement with this mechanism, fumarate had little effect on the apparentK ; of oxalacetate (Fig. 11, curue A; and Table VI); and in the presence of fumarate, saturating oxalacetate inhibited only 70%. Therefore, oxalacetate and fumarate are not both bound

Regulation of Hepatoma Glutamate-Malate Metabolism

10428

CoA was inhibitory in the presence of fumarate. At 1.0 mM levels, ATP and, to a lesser extent, ADP were inhibitors in the presence or absence of fumarate. Malate Dehydrogenase Versus Malic Enzyme Activity-As 5 O shown in Table VI1 and previously (7, 9, 13), in Morris 7777 mitochondria and in mitochondria of other rapidly dividing tumors, malate dehydrogenase activity is in vast excess over that of NAD(P) malic enzyme. Under conditions more physI I I iological than thoseused t o obtain the resultsshown in Table 2.5 5.0 7.5 10 VII, theratio of malate dehydrogenase to NAD(P) malic [Modifier] mM enzyme in Morris7777 mitochondria would be extremely high. FIG. 10. Plots of specific activity of NAD(P) malic enzyme versus modifier concentration. Fumarate and succinatewere the Using the resultsshown in Table VI1 plus the assaysof pure inthispaper,itcan be varied modifiers used in curues A and C, respectively. Curve A shows NAD(P) malicenzymedescribed of 1.0 mM NAD, 1.0 mM the results obtained when the concentration of succinate was in- calculated that in the presence creased in the presence of 5.0 mM fumarate. Remaining experimental malate, 5.0 mM fumarate, 2.0 mM MgC12, 0.1 mM acetyl-coA, conditions were 1.0 mM NAD, 1.0 mM malate, 20 mM potassium and 20 pg/ml citrate synthase (pH 7.0) at 25 "C, the specific phosphate, 2 mM MgC12, 0.1 mM EDTA, and 0.5 mM dithiothreitol activity of NAD(P) malic enzyme in the tumor mitochondrial (pH 7.0) at 25 "C. The solid curues were calculated with the use of extract would be 0.04 nmol/min/mg of mitochondrial protein. Equation 2 and the values of the constants shown in Table VI. Since fumarate and MgC12 have little effect on malate dehydrogenase (24), the specific activity of malate dehydrogenase TABLE VI in the extract under these conditions (citrate synthase plus Modifier constantsof tumor mitochondrialNAD(P) malic enzyme acetyl-coA present to react with oxalacetate) would be essenThe constantK refers tothe activator or inhibition constant. The tially equal to that shown in Table VI1 (Method 111) or 4 terms V , V, and V,,' are the velocity in the absence of modifier, velocity in the presence of saturating modifier, and velocity in the orders of magnitude higher than that of NAD(P) malic enpresence of 5.0 mM fumarate plus saturating second modifier, respec- zyme. Although the activity of NAD(P) malic enzyme would tively. The values of the constants were obtained from the results be -%fold higher if Mn2+were substituted for M$+ (7) and shown in Figs.10 and 11and Equation2 as described under "Materials would also be higher at a higher pH or temperature, increasing and Methods." Assays were performed in the presence of 1.0 mM the pH and temperature also increases malate dehydrogenase NAD and 1.0 mM malate. Remaining experimental conditions were 20 mM potassium phosphate, 2 mM MgC12, 0.1 mM EDTA, and 0.5 activity (Table VII). However, pyruvate is nota potent inhibitor of NAD(P) malic enzyme (Table V), whereas the Ki of mM dithiothreitol (pH 7.0) at 25 "C. oxalacetate from NADH:malate dehydrogenase at a physioVaried Additions logical p H is so low that it is difficult to measure directly with modifier Kiof oxalacetate can, howconventional methods (24). The None 0.59 5.3 Fumarate ever, be estimated by taking advantage of the fact the malate None 1.7 2.9 Succinate dehydrogenase reaction is an Ordered Bi Bi reaction, where 0.71 (5.0 mM) High Succinate Fumarate Oxalacetate None 0.18 0 NAD adds before malate, and the rate-limiting step isdissoOxalacetate Fumarate (5.0 mM) 0.14 0.30 ciation of NADH from the enzyme (34,35). According to the rate equation for this mechanism (36), when NADH is saturating and malate is added asa product inhibitor, the recipfrom the rocal of the Ki of oxalacetatecanbeobtained intersection pointof double-reciprocal plots of velocity versus oxalacetate concentration. These plots, in the presence of 400 PM NADH (which was found independently to be a level of NADH -10-fold higher than its K,) and 0-6.0 mM malate, are shown inFig. 12. The intersection point corresponds toa v Kiof oxalacetate of 5 PM. Inhibition by malate in these assays 0 25 was specific in that even 10 mM levels of aspartate had no effect on malate dehydrogenase activity (data not shown). In addition to being inhibited considerably less by its keto acid product, NADH (especially in the presenceof fumarate), citrate, and glutamate were considerably lesspotent inhibitors of NAD(P) malic enzyme (Table V) than was found to be the 0.5 IO case previously with malate dehydrogenase (20, 24, 33, 35). [~xo~acetote] ~ M - I However, physiological levels of these inhibitors in addition FIG. 11. Plots of specific activity of NAD(P) malic enzyme to oxalacetate would not be expected to reduce malate dehyuersus oxalacetate concentration. These assays were performed level even close in the presence (curue A ) or absence (curue B ) of 5.0 mM fumarate. drogenase activity in tumor mitochondria a to of NAD(P) malic enzyme. Furthermore, the fact that to that Remaining experimental conditions are described in the legends to than Fig. 10 and Table VI. The solid curues were calculated with the use malate dehydrogenase is considerablymorereactive of Equation 2 and the values of the constants shown in Table VI. NAD(P) malic enzyme with malate generated internally by fumarase (1)in tumor mitochondria, even in the absence of to the same site of the same enzyme-substrate or enzyme- low energy or State 3 conditions, indicates that malatedehyproduct complex; and consequently, both fumarate andoxal- drogenase is not inhibited to the extent that it is less active than NAD(P) malic enzyme. acetate can simultaneously associate with theenzyme. Although the kinetic properties of malate dehydrogenase All other metabolites tested were either inhibitory or had no effect (Table V). At 0.2 mM levels, only succinyl-CoA was describedabove were obtained with malate dehydrogenase is apparently no inhibitory in the presence or absenceof fumarate, andacetyl- purified from normal mitochondria, there I

o

O

I

1

I

I

10429

Regulation of Hepatoma Glutamate-Malute Metabolism TABLEVI1 Leuek of enzymes in liuer and Morris 7777 hepatoma mitochondrial extracts Mitochondrial extracts were prepared and assays were performed as described under "Materials and Methods" and in Ref. 31. For some enzymes, there was a wider range of values in the hepatomas than in liver. Therefore, the ranges of values in the hepatomas are shown. Method

Assay conditions

Enzyme

.

Specific activity Substrate Heuatoma

T

UH ~~

Mmol prodwt/min/mg mitochondrial protein

"C

111

NAD(P)-ME"25 25

7.4 NADP 7.4 NAD' 7.2 30 NADP 1.3 9Oxalacetate 7.8 Malate Oxalacetate 7.6 30 7.0 Oxalacetate 7.0 Malate 7.5 30 Pyruvate 0.054 8.1 30 Oxalacetate 7.8 Aspartate 7.6 30 Aspartate 7.8 0.12 30 Alanine 0.02 7.8 NADH 7.0 NADH 7.5 30 1.0-1.5 NAD 0.13-0.19 7.8 Malate 0.62 7.5 30 Pyruvate 7.2 2.2 NAD 0.11 7.5 30 NADP 7.0 0.18 Ornithine 0.60

I 25

MDH 7.8 25

I11

25 25

111

I I I1 I I

PDHC

cs

AspAT

25

AlAT GDH

I1 I1 I

I1

25 30

I I

Liver

Activity hepatoma activity liver

7 0.79 12.21.3-1.8 0.041 0.31 1.5-2.2 0.6 2.1 0.6 3.3 0.16 0.40 1.3 1.7 0.41-0.59 0.13 0.22 0.30 0.05 2.7-3.2 0.16 3.4

0.016 0.021 0.033

High

1.1 16-22 6 0.4

1.4

1.3 0.48-0.67 1.3 2.0 0.52 0.7-1.0

KDHC Fumarase 25 I1 2.8 PC I 0.01 0.03 NAD:IDH 30 I 0.43-0.52 NADP:IDH I 30 OTC I NAD(P)-ME, NAD(P) malic enzyme; MDH, malate dehydrogenase; PDHC, pyruvate dehydrogenase complex; CS, citratesynthase; AspAT, aspartate aminotransferase; AlaAT, alanine aminotransferase; GDH, glutamate dehydrogenase; KDHC, a-ketoglutarate dehydrogenase complex; PC, pyruvate carboxylase; NAD:IDH, NAD:isocitrate dehydrogenase; NADP:IDH, NADP:isocitrate dehydrogenase; OTC, ornithine transcarbamylase. 'The assay was not actually performed, but was calculated from the ratio of the performed assays to the indicated assay with pure enzyme. r

t

I

-0.20

1

I

-0.m

0

0.10

,

l

0.20

I/[OxaIacetate]pM"

FIG. 12. Double-reciprocal plots of velocity (change in absorbance at 340 nm/min) of mitochondrial malate dehydrogenase uersus oxalacetate concentration. These assays were performed in the presence of 400 p~ NADH and 6.0,4.0, 2.0, and 1.0 mM malate (curues A-D, respectively). The results obtained in the absence of added malate are shown in curve E. Remaining experimental conditions were 0.01 pg/ml pig heart mitochondrial malate dehydrogenase, 10 pg/ml bovine serum albumin, 20 mM potassium phosphate, and 0.1 mM EDTA (pH 7.0) at 25 "C.

major kinetic difference between rat liver and hepatoma malate dehydrogenases. In bothcases, we found the K,,, of malate, the ratio of activity of the forward and reverse reaction, and inhibition by citrate and glutamate to be the same (data not shown). Effect of Pyruvate Dehydrogenase Complex-As shown in Table VIII, the pyruvate dehydrogenase complex activates NAD(P) malic enzyme. In these assays, acetyl-coA was not present, malate was not oxidized when malic enzyme was not added, and the level of the pyruvate dehydrogenase complex required for activation (20 pg/ml or 2.8 nM) was quite low (Table VIII). Therefore, the increase in malic enzymeactivity

TABLE VI11 Activation of NAD(P) malic enzyme by pyruvate dehydrogenase complex Assays were performed in the presence of 1.0 mM NAD and 1.0 mM malate. The level of malic enzyme (ME) was 2.5 pg/ml. The levels of the pyruvate dehydrogenase complex (PDHC), a-ketoglutarate dehydrogenase complex (KDHC), glutamate dehydrogenase (GDH), and citrate synthase (CS) were each 20 pg/ml. Remaining experimental conditions were 20 mM potassium phosphate, 2 mM MgCl,, 0.1 mM EDTA, and 0.5 mM dithiothreitol (pH 7.0) at 25 "C. Additions

Specific activity

+mol/min/mg

None PDHC PDHC - ME KDHC GDH

cs

PDHC

+ CS

0.09 0.18 0 0.09 0.08 0.10 0.17

apparently results from binding of the large pyruvate dehydrogenase complex (M,= 7 x lo6) (37) to NAD(P) malic enzyme ( M , = 2.4 x lo5) (8, 13) and is not a consequence of the pyruvate dehydrogenase complex reacting with NAD plus pyruvate, a contaminating malate-oxidizing enzyme, or the pyruvate dehydrogenase complex decreasing inhibition of the malic enzyme by its products. Activation was specific in that glutamate dehydrogenase, the a-ketoglutarate dehydrogenase complex, andcitratesynthase were notactivators(Table VIII). Activation of NAD(P) malic enzyme by the pyruvate dehydrogenase complex could also take place in Morris 7777

10430

Regulation of Hepatoma Glutamate-Malate Metabolism

mitochondria. Although citrate synthase also associates with the pyruvate dehydrogenase complex (38), it did not prevent the pyruvate dehydrogenase complex from activating NAD(P) malic enzyme. Furthermore, it can be calculated from the specific activity of the pure enzymes and the data of Table VI1 (using previously described methods) (31) that the level M of NAD(P) malic enzyme would be 1.5 mg/ml or 5.6 ~ L and that the level of the pyruvate dehydrogenase complex would be 3 mg/ml or 0.4 PM in the tumor mitochondria. These concentrations areconsiderably higher than those used in our experiments; and assuming multiple malic enzyme-binding sites on the extremely large pyruvate dehydrogenase complex, the level of this complex could be sufficiently high to associate with a significant fraction of the NAD(P) malic enzyme. Levels of Other Enzymes in Morris 7777 MitochndriaThe mitochondrial levels of enzymes that could play a role in the oxidation of glutamate and malate in Morris 7777 hepatomas areshown in Table VII. It can be seen that thelevel of the pyruvate dehydrogenase complex was about the same in both the hepatoma and ratliver, but theactivities of enzymes that catalyze the reactions of the Krebs cycle from fumarate to succinyl-CoA, especially isocitrate dehydrogenases, were significantly higher inthe hepatoma (aconitase, which is difficult to assay in extracts,was not measured). Alternatively, pyruvate carboxylase was almost absent; and the levels of activities of enzymes involved in glutamate-NH: metabolism, such as aspartate aminotransferase, glutamate dehydrogenase, ornithine transcarbamylase, and especially alanine aminotransferase, were significantly lower in Morris 7777 mitochondria than in liver mitochondria (Table VII). It was demonstrated previously (39) that thelevel of carbamyl-phosphate synthase I is also quite low in hepatoma mitochondria. The differences found between the levels of enzyme activities in hepatoma versus liver mitochondria (Table VII) were not artifacts produced by the procedures employed to prepare and extract mitochondria. If this were the case, then itwould not be expected that the ratio of enzyme activity in liver mitochondria to that in hepatoma mitochondria wouldbe high in some cases and low in others. Furthermore, comparable ratios were found when enzymes were extracted and assayed with several different methods (see “Materials and Methods” and Table 11).The major method used (Method I) to prepare mitochondria does notrupture the liver outer mitochondrial membrane, and electron micrographs of hepatoma mitochondria prepared with Method I (data notshown) also revealed that digitonin removed the bulk of the contaminating vesicles without rupturing the hepatoma outer mitochondrial membranes. Based upon the citrate synthase assay, we recovered 58 mg of mitochondrial protein/g of hepatoma homogenate protein with a 54% recovery. This gives a value of 107 mg of mitochondrial protein/g of homogenate protein, which would be lower than the value other investigators found with liver (40) and half the value we found with liver (31), but consistent with the observation that hepatomas have %fold less mitochondria than liver (41). DISCUSSION

Previous kinetic studies of cytosolic malic enzymes were consistent with an ordered mechanism being the predominant reaction pathway for the forward reaction, as shown in Mechanism I1 (42,43). The tumor mitochondrial malic enzyme also probably catalyzes a predominantly ordered reaction because it has an extremely low affinity for a malate affinity column unless oxidized pyridine nucleotide is also present to promote binding (13). Furthermore, in the absence of fumarate, the

e

MECHANISM 11. A , oxidized pyridine nucleotide;B , malate; P, CO,; Q, pyruvate; R, reduced pyridine nucleotide;kl-klo, rate constantsfor

the indicated steps.

K , of malate is considerably lower in the presence ofNAD than in the presence of NADP, which indicates that the coenzyme plays a major role in determining the affinity of malate for the enzyme. In addition, in the presence of fumarate, NADH was competitive with NAD and non-competitive with malate, which is consistent with the ordered mechanism (42, 43). The rate-limiting step in the ordered malic enzyme reaction (43), and in many other dehydrogenase reactions, is dissociation of the reduced coenzyme from the enzyme ( 4 ) . The low Ki of NADH and potent inhibition of the tumor malic enzyme by both NADPH and NADH are consistent with this also being the case with the tumor malic enzyme. When NAD was the coenzyme, the extrapolated maximal velocity was essentially the same in the presence of infinite NAD and constant high malate or infinite malate and in the presence of constant high NAD, indicating in both cases that the two substrates were saturating. Fumarate had little effect on the K,,, of NAD, but both the K,,, of malate and Vma.were increased -1.5-fold by fumarate. According to the rateequation for Mechanism I1 (with ks or dissociation of NADH being rate-limiting), the values of the maximal velocity ( V ) ,Michaelis constant ofNAD (&), and Michaelis constant of malate (KB)are asfollows: V = 4, Ka = h / k l , and KB = ks( ( i t 4 + kg)/&). Thus, these results are consistent with fumarate activating by enhancing dissociation of NADH (increasing ks so V,,, and KBare both increased 1.5-fold) and increasing k l , the rate of association of NAD with the enzyme, so that KA or 4 / k l is not altered. In addition to the steps shown in Mechanism 11, malate apparently also associates with an allosteric site, where it could activate by increasing dissociation of reduced coenzyme. Similar kinetic patterns would have been obtained, when the concentration of malate was varied, if there were cooperative interaction between the binding sites on the four enzyme subunits or if, instead of associating with an allosteric site, malate associated with the active site of E . NADH ( E R )and enhanced dissociation of NADH. However, the latter mechanism would require that malate canreadily associate with the free enzyme ( E ) , which, as mentioned above, is apparently not the case. NADH is apparently also bound to aninhibitory allosteric site on the enzyme because when the level of NAD was low, there was considerably more inhibition by NADH than could be accounted for on the basis of a single NADH-binding site. However, binding of either fumarate or malate to their allosteric site apparently inhibits binding of NADH to its allosteric site. Consequently, in the presence of fumarate, plots of the reciprocal of velocity versus NADH concentration in the presence of various levels of NAD werelinear. In addition, when fumarate was absent and the level of NAD was sufficiently high to prevent binding of NADH to its active site (but not to itsallosteric site), plots of the reciprocal velocity

Regulation of Hepatoma Glutamate-Malate Metabolism versus NADH concentration were linear in the presence of various concentrations of malate, andmalate was almost competitive with NADH. If, however, in the absence of fumarate the level ofNAD was decreased, then plots of the reciprocal of velocity versus NADH concentration were not linear, indicating that lowering the level of NAD permitted binding of NADH to theactive site and also decreased binding of malate. Decreased binding of malate, in turn, permitted NADH to associate with the NADH allosteric site. Succinate is also an activator, but is competitive with and less effective than fumarate. Allof the other metabolites tested were inhibitors or had no effect. Of these, oxalacetate was the most potent. However, the Ki of oxalacetate (140-180 p ~ is)probably higher than itsfree mitochondrial level (44), especially in theMorris 7777 hepatoma, which lacks pyruvate carboxylase (Table VII) and channels exogenous malate into NAD(P) malic enzyme. Alternatively, the level of succinylCoA required for inhibition (0.2 mM) is lower than itslevel in liver mitochondria (0.3-1.4 mM) (45). Differences among NAD(P) Malic Enzymes-In previous studies of the adrenal cortex mitochondrial NAD malic enzyme (46, 47) and several tumor (22 aH, Ehrlich, and AS30D) NAD(P) malic enzymes (8), no evidence was presented that suggested an allosteric malate site. Fumarate appeared to lower the K,,, values of malate and NAD with the adrenal NAD malic enzyme, and themain effect of fumarate with the tumor NAD(P) malic enzyme was to produce a marked (510-fold) decrease in theK,,,values of malate, NAD, and NADP (8,46,47). On the basis of these kinetic experiments and the behavior of the 22 aH enzyme on an affinity column, investigators (8) concluded that the main action of fumarate is to enhance binding of coenzyme andmalate to the enzyme. These results are considerably different from those of our study of the Morris 7777 mitochondrial NAD(P) malic enzyme under comparable assay conditions. In this case, when NAD was the coenzyme, fumarate did not markedly change the K,,, ofNAD and slightly increased the K,,, of malate. However, the K,,, values of malate and NAD (0.8 and 0.028 mM, respectively) with the Morris 7777 enzyme were lower than the K,,, values of malate and NAD (3.6 and 0.055 mM, respectively) with the other tumor NAD(P) malic enzymes (8). Although product inhibition and detailed studies of the effects of fumarate and other regulators have only been performed in our study, these results indicatethat when NAD is the coenzyme, the othertumor enzymes have a comparatively lower affinity for NAD and, in turn, malate and that consequently, the main effect of fumarate is to decrease the K , values ofNAD and malate. In contrast, the main effect of fumarate with the Morris 7777 enzyme is apparently to enhance dissociation of NADH from the enzyme. When NADP is thecoenzyme, the Morris 7777 enzyme reacts, as the other tumor enzymes, in that the K,,, of malate is high; there was no evidence of an allosteric malate site, and fumarate markedly decreased the K,,,of malate. In previous studies, ATP was found to be a competitive inhibitor of malate with both the tumor ( K i = 80 PM) and adrenal cortex (Ki = 0.3 mM) enzymes (8, 46, 47). However, in our study, considerably higher (-1.0 mM) levels of ATP were required for significant inhibition of the Morris 7777 enzyme in the presence and absence of fumarate. Regulation by Hetero-enzymeInteraction-According to our results, the preferred reactivity of NAD(P) malic enzyme versus malate dehydrogenase with exogenous malate in tumor mitochondria cannot be readily explained on the basis of the kinetic propertiesof the two enzymes or the levels of activity of the two enzymes in tumor mitochondria. However, a pos-

10431

sible explanation is (as we have proposed previously (24, 31, 48) on the basis of experiments performed by us (48) and others (38, 49-52) with pure enzymes) that the only malate dehydrogenase that would be active with NAD plus malate would be the fraction of the total malate dehydrogenase that is not membrane-bound or free but is localized in the matrix as a consequence of associating with membrane-hetero-enzyme complexes between the a-ketoglutarate dehydrogenase complex and aspartate aminotransferase or the pyruvate dehydrogenase complex andcitratesynthase. Association of malate dehydrogenase with these hetero-enzyme complexes would provide malate dehydrogenase with a mechanism for the removal of oxalacetate and also results in an increase in malate dehydrogenase activity (24). At a physiological pH, malate dehydrogenase cannot even be readily assayed in the absence of enzymes that react with its products (24). On the other hand, some NAD(P) malic enzymes apparently have a high affinity for the membrane (53); the equilibrium of the malic enzyme reaction is 3 orders of magnitude more favorable than that of malate dehydrogenase (54, 55); and pyruvate is notapotent product inhibitor of NAD(P) malicenzyme (Table V). Therefore, NAD(P) malic enzyme may be localized in the vicinity of the membrane, where its thermodynamic and kinetic properties would enable it to readily intercept malate from malate dehydrogenase as malate passes through the membrane. Furthermore, according to our results, the pyruvate dehydrogenase complex, which has a high affinity for the inner mitochondrial membrane (56), could, by also associating with NAD(P) malic enzyme, not only increase NAD(P) malic enzyme activity, but also play a role in localizing NAD(P) malic enzyme in thevicinity of the membrane. Energy Metabolism in Morris 7777 Hepatorna-Morris 7777 hepatomas, as other rapidly dividing tumors, can utilize glutamineasa major metabolic fuel (1-5). According to our results, oxidation of glutamate would have several obstacles in Morris 7777 hepatomas because alanine aminotransferase activity is quite low, pyruvate carboxylase activity is almost absent, and the level of aspartate aminotransferase is also significantly lower in Morris 7777 mitochondria than in liver mitochondria. Therefore, in the presence of malate and mitochondrial levels of glutamate, which can be as low as 6.0 mM, and levels of aspartate and a-ketoglutarate,which under the same conditions can be 9.0and 3.0 mM, respectively (57), aspartate aminotransferase, which can have a K,,, for glutamate as high as 20 mM (23), may not be capable of competing with citrate synthase for oxalacetate. Furthermore, the quite low levels of alanine aminotransferase and pyruvate carboxylase activities plus the adequate level of pyruvate dehydrogenase activity and possibly the observed interaction between the pyruvate dehydrogenase complex and NAD(P) malic enzyme described in this paper would enhance the probability that pyruvate generated by NAD(P) malic enzyme would be utilized to provide citrate synthase with acetyl-coA. In addition, in the presence of lowlevels of glutamate and low-energy or State 3 conditions, malate dehydrogenase, the pyruvate dehydrogenase complex, and isocitrate dehydrogenases would be quite active; and thisplus the high levels of these enzymes and citrate synthasecompared with liver mitochondria would promote the synthesis andoxidation of citrate. Consequently, Morris 7777 mitochondria (4), unlike 3924A hepatoma mitochondria (58), do not significantly export citrate for cholesterol synthesis, but insteadoxidize citrate, perhaps as acompensatory energy-generating mechanism. Potent inhibition of NAD(P) malic enzyme (our results) and both isocitrate dehydrogenases (59) by the NADPH generated by the high level of NADP:isocitrate dehydrogenase could be overcomeby glu-

10432

Regulation of Hepatoma Glutamate-Malate Metabolism

tamate dehydrogenase, which in mitochondria can preferentially reactwith NADPH (60, 61). In addition, since aketoglutarategeneratedbyNADP:isocitratedehydrogenase cannot be readily oxidized by the Krebs cycle, but can react with glutamate dehydrogenase (59, 62), the reductive amination of a-ketoglutarate would provide aspartate aminotransferase with the glutamate needed for it to provide the Krebs cycle with a-ketoglutarate. The reactivity of glutamate dehydrogenase with NADPH and a-ketoglutarate is high under low energy State 3 conditions and considerably more active in State 3 than in high energy State 4 conditions (60). In addition, the level of NH: would be expected to be high in a hepatoma that has a high level of glutaminase (4) and is deficient in carbamyl-phosphate synthase I and ornithine transcarbamylase activities (39). Since the K , ofNH:forglutamatedehydrogenase is high and -20 mM (63))the high level of NH: would further promote the reductive aminationof a-ketoglutarate. Acknowledgment-We thank Dr. Enrique Valdivia for performing the electron microscopy.

REFERENCES 1. Moreadith, R.W., and Lehninger, A.L. (1984) J. Biol. Chem. 269,6215-6221 2. Kovacevic, Z., and Morris, H. P. (1972) Cancer Res. 32,326-333 3. Reitzer, L. J., Wice, B. M., and Kennell, D. (1979) J. Biol. Chem. 254,2669-2676 4. Mares-Perlman, J. A., and Shrago, E. (1988) Cancer Res. 48, 602-608 5. Kovacevic, 2. (1971) Biochem. J. 1 2 5 , 757-763 6. Board, M., Humm, S., and Newsholme, E. A. (1990) Biochem. J. 265,503-509 7. Sauer, L.A., Dauchy, R. T., Nagel, W. O., and Morris, H. P. (1980). J. Biol. Chem. 255,3844-3848 8. Moreadith, R.W., and Lehninger, A.L. (1984) J. Biol. Chem. 259,6222-6227 9. Hansford, R. G., and Lehringer, A.L. (1973) Biochem. Biophys. Res. Commun. 51,480-486 10. Lazo, P. (1981) Eur. J. Biochem. 1 1 7 , 19-25 11. Linder-Horowitz, M.,Knox, W.E., and Morris, H. P. (1969) Cancer Res. 2 9 , 1195-1199 12. Wice, B. M., Reitzer, L. J., and Kennell, D. (1981) J. Biol. Chem. 256,7812-7819 13. Teller, J. K., and Fahien, L. A. (1990) Protein Expression Purification 1, 151-154 14. Kovacevic, Z., Brkliac, O., and Bain, K. (1991) Biochem. J. 2 7 3 , 271-275 15. Swick, R. W., Barstein, P. L., and Stange, J. L. (1965) J. Biol. Chem. 240,3334-3340 16. Seiss, E. A., Nimmannit, S., and Weiland, 0.H. (1976) Cancer Res. 3 6 , 55-59 17. Lazo, P. A., and Sols, A. (1980) Biochem. J. 1 9 0 , 705-710 18. Baggetto, L. G., and Lehninger, A. L. (1987) J. Biol. Chem. 2 6 2 , 9535-9541 19. Fahien, L.A., MacDonald, M. J., Teller, J. K., Fibich, B., and Fahien, C. M. (1989) J. Biol. Chem. 2 6 4 , 12303-12312 20. Fahien, L. A., and Stremecki, M. (1969) Arch. Biochem. Biophys. 130,478-487 21. Stanley, C. J., and Perham, R. W. (1980) Biochem. J. 191, 147154 22. Fahien, L. A., Stremecki, M., and Smith, S. E. (1969) Arch. Biochem. Biophys. 130,449-453 23. Fahien, L. A., and Stremecki, M. (1969) Arch. Biochem. Biophys. 130,456-467 24. Fahien, L. A., Kmiotek, E. H., MacDonald, M. J., Fibich, B., and Mandic, M. (1988) J. Biol. Chem. 2 6 3 , 10687-10697

25. Lowry, 0. H., Rosebrough, N. J., Farr, A.L., and Randall, R. J. (1951) J. Bwl. Chem. 193,265-275 26. Layne, E. (1957) Methods Enzymol. 3,450-451 27. Frieden, C. (1964) J. Biol. Chem. 239,3522-3531 28. Fahien, L. A., and Shemisa, 0.A. (1970) Mol. Phurmacol. 6,156163 29. Cleland, W. W. (1979) Methods Enzymol. 63,103-128 30. Fahien, L. A., and Cohen, P. P. (1964) J. Biol. Chem. 239,19251934 31. Fahien, L. A., and Teller, J. K. (1992) J.Biol. Chem. 267,1041110422 32. Denyer, G. S., Kerby, A. L., and Randle, P. J. (1986) Biochem. J. 239,347-354 33. Zolnierowicz, S., Swierczynski, J., and Zelewski, L. (1988) Biochem. Med. Metab. Biol. 39,208-216 34. Silverstein, E., and Suleke, G. (1969) Biochemistry 8, 2543-2549 35. Silverstein, E., and Suleke, G. (1969) Biochim.Biophys. Acta 185,297-303 36. Cleland, W. W. (1963) Biochim. Biophys. Acta6 7 , 173-187 37. Reed, L. J., and Petit,F. H. (1981) Cold Spring Harbor Conf. Cell Proliferation 8 , 701-711 38. Sumegi, B., Gyocsi, L., and Alkonyi, I. (1980) Biochim. Biophys. Acta 616,158-166 39. Lawson, D., Paik, W. K., Morris, H. P., and Weinhouse, S. (1975) Cancer Res. 3 5 , 156-163 40. Leighton, F., Poole, B., Beaufay, H., Baudhuin, P., Coffey, J. W., Fowler, S., and DeDuve, C. (1968) J. Cell Biol. 37,482-513 41. Pedersen, P. L. (1978) Prog. Exp. Tumor Res. 2 2 , 190-274 42. Hsu, R. Y., Lardy, H. A., and Cleland, W.W. (1967) J. Biol. Chem. 242,5315-5322 43. Schimerlik, M. I., Grimshaw, C. E., and Cleland, W. W. (1977) Biochemistry 16,571-582 44. Srere, P. A. (1976) in Gluconeogenesis: Its Regulation in Mammalian Species (Hanson, R. W., and Melman, M. A., eds) pp. 153-161, John Wiley & Sons, New York 45. Barritt, G. J., Zander, G. L., and Utter,M. F. (1976) in Gluconeogenesis: Its Regubtion in MammalianSpecies (Hanson, R. W., and Mehlman, M. A.) pp. 3-41, John Wiley & Sons, New York 46. Sauer, L. A. (1973) FEBS Lett. 3 3 , 251-255 47. Sauer, L.A. (1973) Biochem. Biophys. Res. Commun. 50, 524531 48. Teller, J. K., Fahien, L. A., and Valdivia, E. (1990) J. Biol. Chem. 265,19486-19494 49. Robinson, J. B., Jr., and Srere, P. A. (1985) J. Biol. Chem. 260, 10800-10805 50. Robinson, J. B., Jr., Inman, L., Sumegi, B., and Srere, P. A. (1987) J. Bwl. Chem. 262,1786-1790 51. Fukushima, T., Decker, R. V., Anderson, W. M., and Spivey, H. 0.(1989) J. Biol. Chem. 264, 16483-16488 52. D’Souza, S. F., and Srere, P. A. (1983) J. Biol. Chem. 258,47064709 53. Nagel, W. O., and Sauer, L. A. (1982) J. Biol. Chem. 257,1240512411 54. Burton, K., and Wilson, T. H. (1953) Biochem. J. 54,86-92 55. Haray, I., Korey, S. R., and Ochoa, S. (1953) J. Biol. Chem. 203, 595-601 56. Sumegi, B., and Srere, P. A. (1984) J. Biol. Chem. 2 5 9 , 1504015045 57. Tischler, M. E., Friedrichs, D., Coll, K., and Williamson, J. R. (1977) Arch. Biochem. Biophys. 184,222-236 58. Parlo, R. A., and Coleman, P. S. (1984) J. Biol. Chem. 259,999710003 59. Smith, C. M., and Plaut, G . W. E. (1979) Eur. J . Bwchem. 97, 283-295 60. Lenartowicz, E. (1979) Biochim. Biophys. Acta586,31-43 61. Hoek, J. B., Ernster, L., DeHaan, E. J., and Tager, J. M. (1974) Biochim. Biophys. Acta 3 3 3 , 546-559 62. Keys, D.A., and McAlister-Henn, L. (1990) J. Bacteriol. 172, 4280-4287 63. Fahien, L. A., and Stremecki, M. (1969) Arch. Biochem. Biophys. 130,468-477